



## Anika Therapeutics Advances Date of Third-Quarter 2010 Financial Results Conference Call to Tuesday, November 9

BEDFORD, Mass., Nov 08, 2010 (BUSINESS WIRE) --

[Anika Therapeutics, Inc.](#) (Nasdaq: ANIK) today announced that it plans to issue its third-quarter 2010 financial results after the close of the market on Monday, November 8, 2010, which is one day earlier than previously announced. The Company plans to hold a conference call the next day (Tuesday, November 9) at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the Company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed.

To listen to the conference call, dial 800-291-5365 (International callers dial 617-614-3922) and use the passcode 62761665. Please call approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available to interested parties through a live audio webcast in the "[Investor Relations](#)" section of Anika's website, [www.anikatherapeutics.com](http://www.anikatherapeutics.com). An accompanying slideshow presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after the conclusion of the call.

The webcast also is being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at [www.earnings.com](http://www.earnings.com), Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ([www.streetevents.com](http://www.streetevents.com)), a password-protected event management site.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., [Anika Therapeutics, Inc.](#) develops, manufactures and commercializes therapeutic products for tissue protection, healing, repair and regeneration. These products are based on [hyaluronic acid \(HA\)](#), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by [ORTHOVISC®](#), a treatment for osteoarthritis of the knee; to surgical aids in the [ophthalmic](#) and [anti-adhesion](#) fields. The company also offers [aesthetic dermal fillers](#) for the correction of facial wrinkles. Anika's Italian subsidiary, Fidia Advanced Biopolymers, S.r.l (FAB), provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. FAB's regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

SOURCE: Anika Therapeutics, Inc.

Anika Therapeutics, Inc.  
Charles H. Sherwood, Ph.D., 781-457-9000  
CEO  
or  
Kevin W. Quinlan, 781-457-9000  
CFO

---

<https://ir.anika.com/Anika-Therapeutics-Advances-Date-of-Third-Quarter-2010-Financial-Results-Conference-Call-to-Tuesday,-November-9>